Global Aesthetic Technology Conference 2025

To drive the in-depth advancement of aesthetic medical technology and facilitate efficient aggregation of innovative resources, the Global Aesthetic Technology Conference 2025 officially opened at the Zhongguancun Exhibition Center in Beijing on 12 June 2025. Co-hosted by Siyu MedTech and Tanmei Yijie, co-organized by Zhongguancun Lianxin Biomedical Industry Alliance, and supported by TusStar and Zhongguancun Science City CGT Industry Incubation Center, the event brought together more than 600 distinguished guests from clinical practice, scientific research, enterprises and investment communities.

Centered on core themes including regenerative materials, medicine-engineering integration and investment and financing mechanisms, the conference carried out multi-dimensional exchanges under the framework of “clinical traction + technology-driven development + industrial translation”. A host of landmark outcomes were unveiled on site, delivering a clear signal: aesthetic medical technology in China is entering a new phase marked by parallel progress in systematic innovation and commercial deployment capability.

Policy Guidance and Collaborative Mechanism Building: Initial Consensus on Industrial Translation

Speeches from policy authorities and frontline clinicians at the opening session set the keynote for the conference: starting from unmet needs and advancing toward translational implementation.

Liu Gang, Deputy Director of the Beijing Medical and Health Technology Development Center, noted that aesthetic medicine, a distinctive segment of Beijing’s medical and health industry, is benefiting from overlapping policy support and resource allocation. He introduced that Beijing has rolled out a suite of policy instruments for the “beauty and health” sector in recent years, including three rounds of medical and health action plans and pilot schemes for streamlined end-to-end review of innovative drugs and devices. A systematic ecosystem has gradually taken shape covering industrial space, financial support, talent recruitment and development, and service frameworks.

Subsequently, Professor Qi Zuoliang, Former President of the Plastic Surgery Hospital, Chinese Academy of Medical Sciences, offered a professional perspective. He reviewed the evolution of plastic surgery from functional reconstruction to aesthetic integration, and emphasized that interdisciplinary collaboration spanning regenerative medicine, materials science, energy-based devices and artificial intelligence serves as the core engine for breakthroughs in aesthetic medical technology. He specifically pointed out that collagen-based products have become a dual hotspot for clinical and industrial development, reflecting an industry-wide shift toward upstream R&D and clinical-orientated innovation.

The conference officially launched the Global Aesthetic Technology Awards 2025. Divided into three categories — the Technology Innovation Award, Innovative Service Award and Innovation Translation Award — the awards showcased cutting-edge achievements of Chinese aesthetic medical technology across materials, equipment, research commercialization and other dimensions.

The 3rd China Plastic Surgery Science and Technology Achievement Translation Competition was launched concurrently. Professor Qi Zuoliang briefly reviewed the history and development of the competition, highlighting the pivotal role of plastic surgery research outputs in advancing the aesthetic medicine sector.

Zhao Yanyong, President of the Plastic Surgery Hospital, Chinese Academy of Medical Sciences, then detailed the eligibility rules and review criteria for this year’s competition. Open to research institutions, universities, start-ups and joint teams engaged in aesthetic and plastic surgery fields, the competition evaluates submissions against four core dimensions: innovation, technical feasibility, market potential and team capacity. To encourage high-quality project applications, this edition introduced a reward package including proof-of-concept validation and animal study support. President Zhao stated that the standardized, transparent competition framework aims to continuously stimulate innovation momentum and accelerate the translation of aesthetic medical technologies into clinical and industrial applications.

Zhao Qing, Founder of Siyu MedTech Healthcare Media, released the 2025 Global Aesthetic Technology White Paper. Offering a global lens to examine technological evolution and China’s development roadmap in aesthetic medicine, the white paper delivers a systematic knowledge framework and strategic reference for the industry.

From policy guidelines and award frameworks to the white paper and project competition, a complete industrial ecosystem anchored in “clinical origination and translation priority” is taking shape. Aesthetic medical technology is transitioning from isolated breakthroughs toward structured, scalable implementation.

From Research Logic to Regulatory Pathways: The Question of “Systematic Collaboration” for Aesthetic Tech Deployment

The aesthetic medicine industry is undergoing a science-led transformation. Frontier areas such as regenerative medicine, biomaterials and stem cell applications are gaining industrial traction, while regulatory evaluation and intellectual property represent decisive factors for success. During the keynote session, five experts from academia, clinical practice, enterprises and legal sectors unpacked critical bottlenecks for translating aesthetic medical innovations.

Professor Yin Hang, School of Pharmaceutical Sciences, Tsinghua University, focused on exosomes, a stem cell-derived technology. He noted that exosomes feature targeted delivery, anti-inflammatory and anti-ageing properties, positioning them as an emerging industrial candidate following conventional stem cell therapies. High purity and preserved bioactivity remain key technical bottlenecks. His team is refining production workflows using peptide probes, flow sorting and clinical screening to advance real-world aesthetic applications.

Professor An Yang, Deputy Director of the Department of Plastic Surgery, Peking University Third Hospital, presented research on naso-orbital cleft repair. Starting with decellularized adipose scaffolds, his team built multi-tissue regeneration pathways to achieve engineering translation for tissue reconstruction. Their proprietary adipose purification system and microneedle delivery platform have demonstrated feasibility in wound repair and tissue transplantation, bridging the gap between regenerative materials research and surgical use.

Professor Zhang Guifeng, Researcher at the Institute of Process Engineering, Chinese Academy of Sciences, approached skin health with a forward-looking view. He argued aesthetic medicine should not be limited to superficial cosmetic intervention, but build systematic intervention models based on the interactive mechanisms of cells, extracellular matrix and microenvironments. His research explores shared ageing pathways linking skin, bone and blood vessels. On the materials front, he advocates combining natural and synthetic materials to enable scientific assessment and precise deployment of functional biomaterials.

Professor Zhang Guifeng, Researcher at the Institute of Process Engineering, Chinese Academy of Sciences

Liu Jiaqi, Head of the Consulting Division at Beijing Baoli Yongchang Pharmaceutical Technology Co., Ltd., broke down clinical evaluation and regulatory pathway selection for aesthetic devices from a practical compliance perspective. He explained that the necessity of clinical trials and eligibility for predicate-device registration must be judged against regulatory rules and evidence packages. Using picosecond laser registration as an example, he illustrated how animal testing data, published clinical literature and accumulated clinical experience can collectively support predicate-device approval, underscoring the essential value of a complete evidence chain for regulatory decisions.

Liu Dandan, Expert Patent Search Consultant at Beijing GaoWo Law Firm, pointed out that patents are designed not merely to validate what an entity can develop, but to block third-party exploitation. She emphasized that holding patents does not guarantee freedom to operate. She recommended freedom-to-operate searches prior to product launch and dynamic patent mapping aligned with technical routes and market priorities to build defensible competitive moats.

The session covered fundamental biological mechanisms, regulatory strategy, manufacturing processes and intellectual property. It illustrated that barriers to aesthetic technology translation are rarely isolated technical hurdles; success relies on coordinated advancement across the industrial system. As multiple speakers remarked, synchronized alignment of scientific research, regulation, clinical practice and market demand is indispensable to establishing predictable commercialization pathways.

Pathway Design: Five Hurdles from Research Concepts to Market-Ready Products

Technical breakthroughs are challenging, yet navigating the sequential barriers from laboratory to clinical adoption and market access poses even greater difficulty. The roundtable session, themed “The Innovation Journey of Aesthetic Medical Technology”, was moderated by Sun Pengfei, Attending Physician at the Plastic Surgery Hospital, Chinese Academy of Medical Sciences. Panelists from investment, academia, material enterprises and regulatory service providers shared insights on core pain points and practical experience in research translation.

Question 1: How do investors assess the investment potential of the aesthetic track?

Shi Heng, General Manager of Jinhuitong Investment Fund, stated that aesthetic medicine is inherently a consumer sector with dual medical and aesthetic attributes. Its underlying logic is shifting from purely discretionary consumption toward refined, personalized functional products. He stressed that the capacity to close the full loop from R&D and manufacturing to sales is the core investment criterion.

In his view, upstream raw material development for aesthetic medicine has entered a phase of diversified exploration. Promising lab results alone are insufficient; investors prioritize translation timelines, batch-to-batch product consistency, process maturity and execution capability. “Ultimately, the question is not whether a market exists, but whether the business model can be reliably scaled.”

Question 2: Why do research outputs frequently fail clinical translation?

Assistant Professor Chen Junge from the School of Engineering Medicine, Beihang University, acknowledged extensive promising preclinical results for exosomes and hydrogels, yet substantial uncertainties remain before clinical entry, especially around ethical review, device registration and evaluation standards.

“Researchers tend to adopt a technology-first mindset and often lack systematic regulatory awareness and familiarity with regulatory terminology,” she said. She highlighted the Beijing Municipal Health Commission’s Exploration Program as a platform connecting academic teams with clinicians and industry partners, enabling researchers to identify genuine clinical pain points at an earlier stage. “Technologies gain acceptance only when they address real needs.”

Question 3: Can established medical materials be directly repurposed for aesthetic applications?

Zeng Sheng, Chairman of Hainan Susheng Biotechnology Co., Ltd., drew on his experience with orthopaedic and neurosurgical biomaterials. While the base composition of orthopaedic implants and aesthetic injectable materials may appear similar, their performance requirements and usage scenarios differ drastically.

“Orthopaedic implants prioritize mechanical strength and long-term in-situ stability, whereas facial injectables demand precise delivery, immediate shaping and tunable degradation profiles.” He cautioned against simplistic repurposing for new anatomical sites. “Existing material libraries can serve as a foundation, but the full development logic must be re-established for aesthetic use cases.”

Question 4: What common misconceptions do regulatory service providers observe in translation projects?

Wu Nan, North China Regional General Manager of Lihekang, noted that academic and startup teams frequently underestimate the complexity, cycle length and cost of registration, testing and clinical validation.

“Teams are eager for rapid launch, yet the fastest route is disciplined, step-by-step compliance,” he advised. Compliance planning should commence alongside technology development. “Scientists do not need to become regulatory specialists, but regulatory experts must join the table from the early design phase.”

Question 5: Why do researchers often overlook intellectual property?

Wu Nan shared a real case in which an academic team rushed to publish papers before securing patents, allowing external parties to file patents covering their core technology. “The product was developed, but the IP rights belonged to someone else.”

Chen Junge echoed this challenge. Academic researchers commonly prioritize publications over patents, while industrial stakeholders hold the opposite priority. “Materials science advances rapidly. Without proactive regulatory and IP positioning, teams can find themselves at a disadvantage.”

Shi Heng added from an investment perspective that clear patent strategy and regulatory literacy are hard metrics for evaluating the commercial potential of research outputs. These factors determine product lifecycle and investor confidence.

Across market due diligence, material adaptation, regulatory strategy and IP protection, the roundtable converged on one core consensus: aesthetic medical innovation has entered an era defined by deliberate pathway design. Meaningful breakthroughs are less about novel concepts and more about reliably moving research through clinical validation, regulatory approval and market adoption to serve patients and consumers.

There is no shortage of innovative technology. What is scarce is a viable deployment roadmap and teams capable of executing it.

Closing Remarks

From foundational research and regulatory pathways to compliance frameworks and investment benchmarks, the Inaugural Global Aesthetic Technology Conference revealed a defining shift. Aesthetic innovation is moving away from the old model focused on commercialization and marketing hype toward a new paradigm grounded in clinical evidence and structured translation.

This transition does not signal cooling market enthusiasm; it reflects industrial rationalization. Enterprises are accounting for extended R&D cycles and compliance costs, academic groups are actively engaging clinicians and regulatory experts, and investors are looking beyond concept novelty to assess end-to-end commercial viability. These changes mark the maturation of an industry where aesthetic medicine is evolving from a pure consumer product category into a multidisciplinary technology sector integrating regenerative medicine, biomaterials and precision medicine.

The conference created a forum for practical challenges and systematic solutions to intersect. Technological innovation is never a solo sprint; it requires multi-stakeholder collaboration. The core value of this inaugural event lies in helping all participants clarify roles and interfaces, to navigate deeper industry waters toward predictable, sustainable innovation.